Torudokimab - Zura Bio
Alternative Names: IL-33 antibody - Zura Bio; LY-3375880; ZB-880Latest Information Update: 20 Aug 2023
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Zura Bio
- Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin-33 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma
- Discontinued Atopic dermatitis
Most Recent Events
- 14 Aug 2023 Zura Bio plans a phase II trial for Asthma in 2024
- 19 May 2023 Discontinued - Phase-II for Atopic dermatitis in France, Czech Republic, Canada, Austria, Argentina, USA, Czech Republic, Germany, Hungary, Italy, Spain, Puerto Rico, Mexico, Japan (SC)
- 19 May 2023 Zura Bio plans to gain US FDA regulatory feedback and alignment for torudokimab on phase II/III designs for Asthma in the US in H2 2023